This is of contextual relevance and lends some credence to the findings of our present study which makes a case for the routine screening for BCL6 gene rearrangement by FISH and protein expression by IHC in all newly diagnosed DLBCL cases in Taiwan, and recommends the molecular or pharmacological targeting of BCL6 as an efficacious therapeutic strategy in managing patients with aggressive DHL regardless of COO in Taiwan. Here, BCL6 is linked to diffuse large B-cell lymphoma.